Sahar Moazenrad - Golestan Rheumatology research center, Golestan University of Medical Sciences, Gorgan, Iran.
Pardis Cheraghali - Golestan Rheumatology research center, Golestan University of Medical Sciences, Gorgan, Iran.

Introduction & Aim :Gastric cancer is the fourth most common cause of cancer-related death worldwide and it remains difficult to cure in Western countries, primarily because most patients present with advanced disease. Metformin is a biguanide hypoglycemic agent that widely used in the treatment of non-insulin-dependent diabetes mellitus. Fluorouracil is a Nucleoside Metabolic Inhibitor. we studied the efficacy of metformin with 5-fluorouracil (5-FU) against cancers. Methods: We used the SNU-1 (gastric carcinoma) and AGS (gastric adenocarcinoma) cell line which was incubated in DMEM supplemented with 10% fetal bovine serum under 5% CO2 and 37℃ temperature. Then AGS treated with 3 different doses of metformin and 5- FU (5, 10 and 50 mM) in 3 different times (24,48 and 72 hours). At least 3 repeated in the same dose of treatment and time done for each group. Cell proliferation was assessed with MTT method. Finally statistical analysis, pair t test, t test and ANOVA were performed by using of spss software. Results: The results were shown that the significant changes cell proliferation between the control groups and treatment groups. (24, 48 and 72h: F= 99.32, 127.30 and 235.72, respectively; all P<0.01) . Metformin treatment enhanced 5-FU-mediated cell growth inhibition (24 h: t = 2.97, P < 0.05; 48 h, t = 4.61, P < 0.01; 72h: t =6.02, P < 0.01). Conclusion : Metformin reduce count of the AGS and SNU-1 cell line of the gastric cancer in a dose-dependent manner.

cancer, AGS , SNU-1 , 5-FU, Metformin